On Monday, Shares of Merck & Co. Inc. (NYSE:MRK), gained 1.28% to $57.61.
TetraLogic Pharmaceuticals Corporation (TLOG), and Merck (MRK), known as MSD outside the United States and Canada, declared they have reached an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic’s SMAC-mimetic, in combination with KEYTRUDA(R) (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is predictable to start in late 2015.
KEYTRUDA and birinapant target different elements of cancer’s block against the immune system. TetraLogic’s birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system’s ability to kill abnormal cells via an extracellular TNF signal. Merck’s KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The projected partnership is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA.
Under the terms of the contract, TetraLogic and Merck, through auxiliaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors. TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA. The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study. Results from the study will be used to determine the path for further clinical development of the combination.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Shares of General Motors Company (NYSE:GM), gained 1.28% to $37.11, during its last trading session.
General Motors Company, and Zagster declared the expansion of the Zagster bike sharing program on GM’s Warren Technical Center. Starting this week, a total of 20 new bikes and seven new stations will be added, bringing the total number of bikes to 70 at 14 stations. The raise is the result of high employee satisfaction and use, which has translated into raised productivity and reduced environmental influence.
The program — the first of its kind from any U.S. automaker — was launched last August to give GM’s 19,000 employees new options for getting to and from its 61 buildings covering the 330-acre campus.
Raised employee productivity and overall satisfaction with the service were the two key reasons for the expansion. According to surveys, Zagster saves each rider between 10 and 30 minutes a day, as it removes the time needed to wait for a shuttle bus and/or walk long distances across campus. These benefits are leading GM to consider expanding the program to its other campuses.
Zagster also leveraged the data and conducted “heat map” analyses of all the rides to determine where most trips began and ended, in addition to popular destinations along the way to identify new locations in addition to where to add bikes to existing locations.
To take part, an employee registers online, then reserves a bike through text message or a smart phone app that provides an access code to unlock the lock box mounted on the bike. Zagster’s geofencing technology, installed at each bike station, is powered by solar energy panels — an energy feature comparable to the large public bike share systems, and unique to the GM/Zagster partnership.
General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. It operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments.
At the end of Monday’s trade, Shares of Progressive Corp. (NYSE:PGR), gained 1.27% to $27.09.
The Progressive Corporation, stated the results for March and the first quarter 2015. The company’s 2015 Annual Investor Relations Meeting is planned to be held on Thursday, May 14, 2015 at 1:00 p.m. eastern time. Registration for the webcast will be accessible later this month.
The company plan to release April results on May 20, 2015, before the market opens. Their April results will comprise the results of ARX Holding Corp. and its auxiliaries, in which they attained a controlling interest.
The Progressive Corporation, an insurance holding company, provides personal and commercial property-casualty insurance, and other specialty property-casualty insurance and related services primarily in the United States.
Finally, Noble Energy, Inc. (NYSE:NBL), ended its last trade with 1.27% gain, and closed at $52.76.
Noble Energy, will host its first quarter 2015 earnings webcast and conference call at 9:00 a.m., Central Time, Tuesday, May 5, 2015. The Company plans to issue its financial and operating results preceding to the market opening on the same day.
Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide. Its principal projects are located in onshore DJ Basin and Marcellus Shale, the United States; the deepwater Gulf of Mexico; offshore West Africa; and offshore Eastern Mediterranean.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
